Centiva Capital LP Buys Shares of 15,635 Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Centiva Capital LP bought a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) in the 3rd quarter, HoldingsChannel reports. The fund bought 15,635 shares of the company’s stock, valued at approximately $80,000.

Several other large investors also recently made changes to their positions in the company. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Adaptive Biotechnologies during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter worth $34,000. Rothschild Investment LLC acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth $36,000. MQS Management LLC bought a new position in shares of Adaptive Biotechnologies in the second quarter worth $36,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock valued at $48,000 after purchasing an additional 11,852 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Up 2.3 %

Shares of ADPT stock opened at $6.30 on Friday. The stock has a 50-day simple moving average of $5.37 and a 200 day simple moving average of $4.57. The stock has a market capitalization of $929.75 million, a P/E ratio of -4.70 and a beta of 1.49. Adaptive Biotechnologies Co. has a fifty-two week low of $2.28 and a fifty-two week high of $7.07.

Analyst Ratings Changes

Several research firms recently weighed in on ADPT. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.